NHS to offer weight-loss jab Wegovy for secondary cardiovascular prevention
NHS Expands Access to Wegovy for Cardiovascular Protection
More than a million people in England at risk of recurrent heart attacks and strokes will soon be eligible for the weight-loss jab Wegovy on the NHS. The National Institute for Health and Care Excellence (NICE) has recommended the weekly injection, also known as semaglutide, as an additional preventative measure for patients with established cardiovascular disease, including serious circulation problems in their legs, and who are classified as overweight or obese (BMI of 27 or higher).
This initiative targets individuals already managing their heart health with existing medications, such as statins, and a healthy diet. Clinical trials have demonstrated that Wegovy can significantly reduce the risk of future cardiovascular events. Tests involving tens of thousands of participants revealed a 20% reduction in heart attacks and strokes when the jab was administered alongside current heart medicines.
Crucially, the benefits were observed early in the trials, prior to substantial weight loss, suggesting that the drug exerts a direct protective effect on the heart and blood vessels. Helen Knight from NICE emphasised the compelling evidence, stating, "The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke."
Patients will be able to self-administer the drug at home using a pen injector. While Wegovy primarily functions as an appetite suppressant by mimicking the GLP-1 hormone, some individuals may experience side effects such as bloating or nausea. The treatment is currently limited to two years on the NHS, with long-term risks still under investigation. A key consideration, however, is the need for sustained lifestyle adjustments, including a healthy diet and regular exercise, to maximise and maintain the benefits.
